Literature DB >> 18031785

N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus.

Antu K Dey1, Kathryn B David, Neelanjana Ray, Thomas J Ketas, Per J Klasse, Robert W Doms, John P Moore.   

Abstract

The native, functional HIV-1 envelope glycoprotein (Env) complex is a trimer of two non-covalently associated subunits: the gp120 surface glycoprotein and the gp41 transmembrane glycoprotein. However, various non-functional forms of Env are present on virus particles and HIV-1-infected cells, some of which probably arise as the native complex decays. The aberrant forms include gp120-gp41 monomers and oligomers, as well as gp41 subunits from which gp120 has dissociated. The presence of non-functional Env creates binding sites for antibodies that do not recognize native Env complexes and that are, therefore, non-neutralizing. Non-native Env forms (monomers, dimers, tetramers and aggregates) can also arise when soluble gp140 proteins, lacking the cytoplasmic and transmembrane domains of gp41, are expressed for vaccine studies. We recently identified five amino acids in the gp41 N-terminal region (I535, Q543, S553, K567 and R588) that promote gp140 trimerization. We have now studied their influence on the function and antigenic properties of JR-FL Env expressed on the surfaces of pseudoviruses and Env-transfected cells. The 5 substitutions in gp41 reduce the expression of non-trimeric gp160s, without affecting trimer levels. Pseudovirions bearing the mutant Env are fully infectious with similar kinetics of Env-mediated fusion. Various non-neutralizing antibodies bind less strongly to the Env mutant, but neutralizing antibody binding is unaffected. Hence the gp41 substitutions do not adversely affect Env structure, supporting their use for making new Env-based vaccines. The mutant Env might also help in studies intended to correlate antibody binding to virus neutralization. Of note is that the 5 residues are much more frequent, individually or collectively, in viruses from subtypes other than B.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18031785      PMCID: PMC2317825          DOI: 10.1016/j.virol.2007.10.018

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  87 in total

1.  A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding.

Authors:  Pin-Fang Lin; Wade Blair; Tao Wang; Timothy Spicer; Qi Guo; Nannan Zhou; Yi-Fei Gong; H-G Heidi Wang; Ronald Rose; Gregory Yamanaka; Brett Robinson; Chang-Ben Li; Robert Fridell; Carol Deminie; Gwendeline Demers; Zheng Yang; Lisa Zadjura; Nicholas Meanwell; Richard Colonno
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-20       Impact factor: 11.205

2.  Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies.

Authors:  Pascal Poignard; Maxime Moulard; Edwin Golez; Veronique Vivona; Michael Franti; Sara Venturini; Meng Wang; Paul W H I Parren; Dennis R Burton
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  Altering expression levels of human immunodeficiency virus type 1 gp120-gp41 affects efficiency but not kinetics of cell-cell fusion.

Authors:  Janet E Lineberger; Renee Danzeisen; Daria J Hazuda; Adam J Simon; Michael D Miller
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

4.  Rational site-directed mutations of the LLP-1 and LLP-2 lentivirus lytic peptide domains in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41 indicate common functions in cell-cell fusion but distinct roles in virion envelope incorporation.

Authors:  Vandana Kalia; Surojit Sarkar; Phalguni Gupta; Ronald C Montelaro
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

5.  Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Authors:  Rogier W Sanders; Mika Vesanen; Norbert Schuelke; Aditi Master; Linnea Schiffner; Roopa Kalyanaraman; Maciej Paluch; Ben Berkhout; Paul J Maddon; William C Olson; Min Lu; John P Moore
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

6.  Conformational changes in env oligomer induced by an antibody dependent on the V3 loop base.

Authors:  Lisa Cavacini; Mark Duval; Leslie Song; Rebecca Sangster; Shi-hua Xiang; Joseph Sodroski; Marshall Posner
Journal:  AIDS       Date:  2003-03-28       Impact factor: 4.177

7.  Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions.

Authors:  Qi Guo; Hsu-Tso Ho; Ira Dicker; Li Fan; Nannan Zhou; Jacques Friborg; Tao Wang; Brian V McAuliffe; Hwei-Gene Heidi Wang; Ronald E Rose; Hua Fang; Helen T Scarnati; David R Langley; Nicholas A Meanwell; Ralph Abraham; Richard J Colonno; Pin-Fang Lin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein.

Authors:  Norbert Schülke; Mika S Vesanen; Rogier W Sanders; Ping Zhu; Min Lu; Deborah J Anselma; Anthony R Villa; Paul W H I Parren; James M Binley; Kenneth H Roux; Paul J Maddon; John P Moore; William C Olson
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site.

Authors:  Carolina Herrera; Catherine Spenlehauer; Michael S Fung; Dennis R Burton; Simon Beddows; John P Moore
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  19 in total

1.  Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides.

Authors:  Xi Chen; Lu Lu; Zhi Qi; Hong Lu; Ji Wang; Xiaoxia Yu; Yinghua Chen; Shibo Jiang
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

2.  Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes.

Authors:  Steven W de Taeye; Gabriel Ozorowski; Alba Torrents de la Peña; Miklos Guttman; Jean-Philippe Julien; Tom L G M van den Kerkhof; Judith A Burger; Laura K Pritchard; Pavel Pugach; Anila Yasmeen; Jordan Crampton; Joyce Hu; Ilja Bontjer; Jonathan L Torres; Heather Arendt; Joanne DeStefano; Wayne C Koff; Hanneke Schuitemaker; Dirk Eggink; Ben Berkhout; Hansi Dean; Celia LaBranche; Shane Crotty; Max Crispin; David C Montefiori; P J Klasse; Kelly K Lee; John P Moore; Ian A Wilson; Andrew B Ward; Rogier W Sanders
Journal:  Cell       Date:  2015-12-17       Impact factor: 41.582

3.  Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.

Authors:  Syna Kuriakose Gift; Daniel P Leaman; Lei Zhang; Arthur S Kim; Michael B Zwick
Journal:  J Virol       Date:  2017-11-30       Impact factor: 5.103

4.  In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Authors:  Daniel P Leaman; Heather Kinkead; Michael B Zwick
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

5.  Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein.

Authors:  Sean X Du; Rebecca J Idiart; Ellaine B Mariano; Helen Chen; Peifeng Jiang; Li Xu; Kristin M Ostrow; Terri Wrin; Pham Phung; James M Binley; Christos J Petropoulos; John A Ballantyne; Robert G Whalen
Journal:  Virology       Date:  2009-10-08       Impact factor: 3.616

6.  A Universal Approach to Optimize the Folding and Stability of Prefusion-Closed HIV-1 Envelope Trimers.

Authors:  Lucy Rutten; Yen-Ting Lai; Sven Blokland; Daphne Truan; Ilona J M Bisschop; Nika M Strokappe; Annemart Koornneef; Danielle van Manen; Gwo-Yu Chuang; S Katie Farney; Hanneke Schuitemaker; Peter D Kwong; Johannes P M Langedijk
Journal:  Cell Rep       Date:  2018-04-10       Impact factor: 9.423

7.  Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein.

Authors:  Per Johan Klasse; Rafael S Depetris; Robert Pejchal; Jean-Philippe Julien; Reza Khayat; Jeong Hyun Lee; Andre J Marozsan; Albert Cupo; Nicolette Cocco; Jacob Korzun; Anila Yasmeen; Andrew B Ward; Ian A Wilson; Rogier W Sanders; John P Moore
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

8.  Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1).

Authors:  Nitish Agrawal; Daniel P Leaman; Eric Rowcliffe; Heather Kinkead; Raman Nohria; Junya Akagi; Katherine Bauer; Sean X Du; Robert G Whalen; Dennis R Burton; Michael B Zwick
Journal:  PLoS One       Date:  2011-06-27       Impact factor: 3.240

9.  Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein.

Authors:  Aemro Kassa; Antu K Dey; Pampi Sarkar; Celia Labranche; Eden P Go; Daniel F Clark; Yide Sun; Avishek Nandi; Karin Hartog; Heather Desaire; David Montefiori; Andrea Carfi; Indresh K Srivastava; Susan W Barnett
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

10.  Increased functional stability and homogeneity of viral envelope spikes through directed evolution.

Authors:  Daniel P Leaman; Michael B Zwick
Journal:  PLoS Pathog       Date:  2013-02-28       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.